Picture of Medios AG logo

ILM1 — Medios AG News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Germany's Medios 9M EBITDA pre falls on price declines

Germany's Medios 9M EBITDA pre falls on price declines


Overview

  • Germany specialty pharma provider's 9M 2026 revenue rose 6.7% yr/yr

  • EBITDA pre fell 5.2% as profitability was impacted by price declines and higher material costs

  • Company confirmed full-year forecast, expects EBITDA pre at lower end of guidance


Outlook

  • Medios sees 2026 revenue between €2.10 bln and €2.16 bln

  • Company expects 2026 EBITDA pre at the lower end of €88 mln to €92 mln range

  • Company expects Hilfstaxe adjustment to reduce Q4 EBITDA pre by about €1.2 mln


Result Drivers

  • PRICE PRESSURE & COSTS - Co said profitability was hurt by price declines in Pharmaceutical Supply and higher material costs in International Business

  • EFFICIENCY PROGRAM - Co said its 'Avanti Medios!' efficiency measures contributed to improved margins in Patient-Specific Therapies

  • SEGMENT GROWTH - Co said revenue growth was driven by all operating segments


Company press release: ID:nEQ4PmrSqa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

EUR 1.63 bln

9M Cash Flow from Operating Activities

EUR 26.20 mln

9M EBITDA

EUR 66.70 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Medios AG is €20.00, about 75.4% above its November 9 closing price of €11.40

  • The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Nov 9 - Biopharma Almirall 9M sales rise on European dermatology growth

  • Nov 9 - US FDA approves Bayer's blood thinner to prevent repeat strokes

  • Nov 9 - UK's Mereo BioPharma Q3 revenue beats expectations


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Medios AG

See all news